

Each drug is recommended for use in combination with other antiretrovirals (except any single-tablet regimen, including Atripla, Biktarvy, Complera, Delstrigo, Genvoya, Juluca, Odefsey, Stribild, Symfi, Śymfi Lo, Symtuza, and Triumeq). For a complete description of DHHS drug recommendations, go to aidsinfo.nih.gov/guidelines. Consult with a physician about which drug therapy and dose is appropriate for you; see drug page or package insert for complete information. Drug chart information is current as of February 1, 2019. Look up your drug by adding its name after you type positivelyaware.com/ into your browser (for example, positivelyaware.com/triumeq).



These medications contain a complete regimen all in one:

SINGLE TABLET REGIMENS (Mutliple drug classes; see pregnancy information for integrase inhibitors below.)



Atripla

RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF)

One tablet (600 mg efavirenz/200 mg emtricitabine/300 mg tenofovir DF), once daily. Take on an empty stomach, preferably at bedtime.



Biktarvy * RECOMMENDED INITIAL REGIMEN

bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) One tablet (50 mg bictegravir/200 mg emtricitabine/25 mg tenofovir alafenamide), once daily. For adults who are treatment-naïve, or on treatment and virologically suppressed for at least 3 months, with no history of treatment failure or resistance mutations associated with components of Biktarvy. Take with or without food.



One tablet (25 mg rilpivirine/200 mg emtricitabine/300 mg tenofovir DF), once daily. Take with a meal.



Delstrigo

RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

doravirine/lamivudine/tenofovir DF (DOR/3TC/TDF) One tablet (100 mg doravirine/300 mg lamivudine/300 mg tenofovir DF),



Genvoya ✓ RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/COBI/FTC/TAF)

One tablet (150 mg elvitegravir/150 mg cobicistat/200 mg emtricitabine/

10 mg tenofovir alafenamide), once daily. Take with food.



Juluca recommended as continuation therapy for people with undetectable hiv viral load for at least 6 months

dolutegravir/rilpivirine (DTG/RPV)

once daily. Take with or without food.

One tablet (50 mg dolutegravir/25 mg rilpivirine), once daily. For adults who are virologically suppressed on a current ART regimen for at least 6 months and who have no history of treatment failure or resistance mutations associated with rilpivirine or dolutegravir. Take with a meal.



Odefsey recommended initial regimen rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF)

One tablet (25 mg rilpivirine/200 mg emtricitabine/25 mg tenofovir alafenamide), once daily. Take with a meal.



Stribild

RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

elvitegravir/cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF)

One tablet (150 mg elvitegravir/150 mg cobicistat/200 mg emtricitabine/ 300 mg tenofovir DF), once daily. Take with food.



Symfi

RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

efavirenz/lamivudine/tenofovir DF (EFV/3TC/TDF)

One tablet (600 mg efavirenz/300 mg lamivudine/300 mg tenofovir DF), once daily. Should be taken on an empty stomach, preferably at bedtime.



efavirenz/lamivudine/tenofovir DF (EFV/3TC/TDF)

One tablet (400 mg efavirenz/300 mg lamivudine/300 mg tenofovir DF), once daily. Should be taken on an empty stomach, preferably at bedtime.



Symtuza ✓ RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

clearance less than 50 mL/min). Take with or without food.

darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DRV/COBI/FTC/TAF) One tablet (800 mg darunavir/150 mg cobicistat/200 mg emtricitabine/

10 mg tenofovir alafenamide), once daily for patients without darunaviror tenofovir- related drug resistance. Take with food



Triumeq ★ RECOMMENDED INITIAL REGIMEN FOR MOST PEOPLE IF HLA-B*5701 NEGATIVE dolutegravir/abacavir/lamivudine (DTG/ABC/3TC)

One tablet (50 mg dolutegravir/600 mg abacavir/300 mg lamivudine), once daily. One additional 50 mg tablet of Tivicay 12 hours apart in people with viral resistance to INSTIs or when taken with certain other medications. Take with or without food.



dolutegravir/lamivudine

initial regimen to consider when ABC, TAF, AND TDF CANNOT BE USED OR ARE NOT OPTIMAL NOT YET APPROVED AT PRESS TIME.

One tablet, once daily. Tablet contains 50 mg of the INSTI dolutegravir plus 300 mg of the NRTI lamivudine. Lamivudine dosing needs to be adjusted for adults and children who have decreased kidney function (creatinine



LONG ACTING REGIMEN

cabotegravir LA/rilpivirine LA ● DHHS RECOMMENDATION (CAB LA/RPV LA) NOT YET APPROVED AT PRESS TIME. Long-acting injection of 400 mg cabotegravir plus 600 mg rilpivirine every $4\,\mbox{or}\,8$ weeks in studies. Dose in studies consisted of two 2 mL injections.

Rilpivirine must be taken with food. Induction phase with oral medication used in research and will be used when approved. Cabotegravir lead-in

These medications must be taken in combination with other HIV meds:

INTEGRASE INHIBITORS (Pregnancy testing should be performed in those of childbearing potential prior to initiation.)



Isentress HD ★ RECOMMENDED AS COMPONENT
OF INITIAL REGIMEN FOR MOST PEOPLE and Isentress



Tivicay ★ RECOMMENDED AS COMPONENT OF INITIAL REGIMEN FOR MOST PEOPLE

dose tablet may not otherwise be available on the market.

dolutegravir (DTG)

One 50 mg tablet, once daily for people on HIV therapy for the first time or treatment-experienced without previous INSTI resistance. Twice-daily dosing for people who have viral resistance to INSTIs or when taken with certain other medications. Take with or without food

PROTEASE INHIBITORS (Boosted and unboosted) Evotaz recommended as component of initial regimen in certain clinical situations

atazanavir/cobicistat (ATV/COBI)

Isentress HD: Two 600 mg film-coated tablets, once daily. Isentress: One 400 mg film-coated tablet, twice daily.

One tablet (300 mg atazanavir/150 mg cobicistat), once daily.



Prezcobix ✓ RECOMMENDED AS COMPONENT OF INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS darunavir/cobicistat (DRV/COBI)

One tablet (800 mg darunavir/150 mg cobicistat), once daily in patients with no darunavir drug resistance. Take with food.



Prezista ✓ RECOMMENDED AS COMPONENT OF INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

One 800 mg tablet with 100 mg Norvir or 150 mg Tybost, once daily for first-time therapy and treatment-experienced adults without Prezistarelated resistance; or one 600 mg tablet plus 100 mg Norvir, twice daily for treatment-experienced people with Prezista-related resistance. Prezista must be taken with Norvir or Tybost. Take with food.



Reyataz Precommended as component of initial regimen in certain clinical situations

atazanavir sulfate (ATV)

GENERIC IS AVAILABLE.

GENERIC IS AVAILABLE

Take with or without food.

GENERIC IS AVAILABLE.

efavirenz (EFV)

GENERIC IS AVAILABLE.

at bedtime.

One 300 mg capsule plus 100 mg Norvir or 150 mg Tybost, once daily; or two 200 mg capsules (without boosting), once daily for treatment-naïve adults (see the POSITIVELY AWARE HIV Drug Guide for details). Take with food. GENERIC IS AVAILABLE.



Tybost

USED ONLY AS A BOOSTER FOR OTHER DRUGS;
RECOMMENDED AS COMPONENT OF INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

raltegravir (RAL)

Take with or without food

Used only for boosting—not an antiretroviral. 150 mg once daily taken at the same time with either Prezista 800 mg or Reyataz 300 mg. Take with food.



USED ONLY AS A BOOSTER FOR OTHER DRUGS;
RECOMMENDED AS COMPONENT OF INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS



Used only for boosting, also an antiretroviral. 100–200 mg, dosed once or twice daily with another PI. Must be taken with food.

NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ("Nukes") ★ All "nukes" are recommended. RECOMMENDED AS A COMPONENT OF INITIAL REGIMEN FOR MOST PEOPLE



RECOMMENDED FOR INITIAL ART FOR MOST PERSONS WHEN COMBINED WITH TIVICAY OR ISENTRESS

One tablet (300 mg lamivudine/300 mg tenofovir DF), once daily,


taken in combination with other ARVs. Take with or without food.

lamivudine/tenofovir DF (3TC/TDF)

emtricitabine/tenofovir alafenamide (FTC/TAF) One tablet (200 mg emtricitabine/25 mg tenofovir alafenamide), once daily. Take with or without food.



RECOMMENDED AS A COMPONENT OF INITIAL REGIMEN FOR MOST PEOPLE






RECOMMENDED AS COMPONENT OF INITIAL REGIMEN FOR MOST PEOPLE WHEN USED IN COMBINATION WITH DOLUTEGRAVIR AND ABACAVIR





lamivudine (3TC) One 300 mg tablet, once daily; or one 150 mg tablet, twice daily. Take with or without food.



Viread RECOMMENDED AS A COMPONENT OF INITIAL REGIMEN FOR MOST PEOPLE

One 25 mg tablet, once daily. Take with a meal.

One 300 mg tablet, once daily. Take with or without food.

tenofovir disoproxil fumarate (TDF)

Take with or without food.



recommended as a component of initial regimen for most people emtricitabine/tenofovir DF (FTC/TDF)



APPROVED AS GENERIC, WHICH IS NOT YET COMMERCIALLY AVAILABLE.

One tablet (200 mg emtricitabine/300 mg tenofovir DF), once daily.



RECOMMENDED AS COMPONENT OF INITIAL REGIMEN FOR MOST PEOPLE IF HLA-B*5701-NEGATIVE WHEN USED IN COMBINATION WITH DOLUTEGRAVIR AND LAMIVUDINE (AS TRIUMEQ)



abacavir sulfate (ABC)



Two 300 mg tablets, once daily; or one 300 mg tablet, twice daily. Take with or without food.





Edurant

RECOMMENDED AS COMPONENT OF INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS IN COMBINATION WITH DESCOVY OR TRUVADA (AS ODEFSEY OR COMPLERA) rilpivirine (RPV)



Intelence

FOR TREATMENT-EXPERIENCED PATIENTS
WITH VIRAL STRAINS RESISTANT TO AN NARTI
AND OTHER ANTIRETROVIRAL DRUGS ONLY



RECOMMENDED AS COMPONENT OF INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS IN COMBINATION WITH DESCOVY OR TRUVADA, OR WITH CIMDUO (AS DELSTRIGO)



etravirine (FTR) One 200 mg tablet, twice daily. Take with food.



doravirine (DOR)



Sustiva

RECOMMENDED AS COMPONENT OF INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS (AS A PART OF ATRIPLA, SYMFI, AND SYMFILO, OR WITH DESCOVY OR TRUVADA)

One 600 mg tablet, once daily. Take on an empty stomach, preferably



GENERIC IS AVAILABLE.

GENERIC IS AVAILABLE.

Selzentry maraviroc (MVC) NOT RECOMMENDED AS

COMPONENT OF AN INITIAL REGIMEN ENTRY INHIBITOR: CCR5 ANTAGONIST

details). Take with or without food.

150, 300, or 600 mg (available in 150 and 300 mg tablets), twice daily, depends on other medications used (see the POSITIVELY AWARE HIV Drug Guide for

One 100 mg tablet, once daily. Take with or without food.



ibalizumab-uiyk (IBA) FOR PEOPLE LACKING SUFFICIENT TREATMENT OPTIONS

CD4 POST-ATTACHMENT INHIBITOR

intravenous infusion. Treatment begins with an IV loading (starting) dose of 2,000 mg, followed by an 800 mg IV infusion maintenance dose given every two weeks thereafter. **LEGACY DRUGS** The following drugs are no longer or rarely prescribed:

Administered once every two weeks via



DHHS RECOMMENDATION NOT YET ESTABLISHED

ATTACHMENT INHIBITOR

fostemsavir

In clinical trials, the investigational dose taken forward for further study was 600 mg, sometimes once daily and sometimes twice daily. Doses were taken after eating. For highly-treatment experienced individuals with history of antiretroviral resistance.

NOT YET APPROVED AT PRESS TIME.





Combivir lamivudine/zidovudine (3TC/AZT)



Fuzeon enfuvirtide (T-20, or ENF)




SOV 500

Invirase

lopinavir/ritonavir (LPV/r)

Kaletra









abacavir/lamivudine/

zidovudine (ABC/3TC/AZT)



didanosine (ddl)

SPONSOR OF THE 2019 POSITIVELY AWARE HIV DRUG CHART







